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OBJECTIVES This study sought to investigate whether pulse pressure (PP) is associated with endothelium-
dependent vasodilation in a group of never-treated hypertensives.
BACKGROUND Pulse pressure represents a well-established independent predictor for cardiovascular mor-
bidity and mortality. Forearm endothelial dysfunction, defined as impaired vasodilating
response to acetylcholine (ACh), may be associated with several cardiovascular risk factors.
Recently, the prognostic value of coronary and forearm endothelial dysfunction has been
demonstrated.
METHODS All patients underwent measurement of blood pressure (BP) both clinically and in an
ambulatory setting. Endothelium-dependent and -independent vasodilation was investigated
by strain-gauge plethysmography in 262 hypertensive patients (age 30 to 55 years) during
intra-arterial infusion of increasing doses of ACh and sodium nitroprusside.
RESULTS We observed that systolic BP rather than diastolic BP significantly induces the PP increase.
Linear regression analysis revealed a significant inverse correlation between ACh-stimulated
forearm blood flow (FBF) and age, body mass index, clinic and monitored systolic BP, and
clinic and monitored PP. However, stepwise multivariate analysis showed that monitored PP
was the strongest independent predictor of ACh-stimulated FBF, accounting for 33.6% of
the variation. After adjustment for other covariates, ACh-stimulated FBF decreases by 8.7%
for each mm Hg increment in monitored PP.
CONCLUSIONS Our data indicate that monitored PP is inversely correlated with ACh-stimulated vasodila-
tion. It is possible to hypothesize that elevation in PP reduces FBF by increasing oxidative
stress and reducing production of nitric oxide caused by reduced shear stress. In addition, the
present findings demonstrate the accuracy of ambulatory BP as a prognostic predictor of
hypertension-associated endothelial dysfunction. (J Am Coll Cardiol 2003;41:1753–8)
© 2003 by the American College of Cardiology Foundation
Pulse pressure (PP), defined as the difference between
systolic and diastolic blood pressure (BP), represents a
well-established independent predictor for cardiovascular
morbidity and mortality (1–4). A possible explanation for
the association between PP and adverse cardiovascular
outcomes may be provided by the concept of bidirectional-
ity: an increased PP is both a cause and a consequence of
atherosclerosis (4).
See page 1759
The vascular endothelium plays a pivotal role in the
regulation of vascular tone and the maintenance of cardio-
vascular homeostasis by the release of some vasoactive
factors. Receptor-dependent agonists—such as acetylcho-
line (ACh), bradykinin, and substance P—and mechanical
stimuli, such as shear stress, relax vascular wall by the release
of nitric oxide (NO), prostacyclin, and endothelium-derived
hyperpolarizing factor (EDHF). The mechanism of action
of EDHF seems to be different from the mechanism of
action of the L-arginine-NO pathway because it involves
calcium-sensitive K channels, which are sensitive to the
combined effects of the apamin and charybdotoxin (5), as
well as cytochrome P450 metabolites (6).
Dysfunction of the vascular endothelium, due to a de-
creased bioavailability of NO, plays an important role in the
appearance and progression of atherosclerosis (7,8). Re-
cently, it has been reported that both coronary (9,10) and
forearm (11) endothelial dysfunction predict long-term
atherosclerotic disease progression and cardiovascular events
rate.
Recent studies have shown an association between PP
elevation and endothelial dysfunction assessed by ACh
reactivity in intact carotid arteries from rabbits (12). How-
ever, no data are available about the association between PP
elevation and ACh-stimulated vasodilation in human hy-
pertension. To these observations, we investigated whether
PP elevation is associated with endothelial dysfunction in a
group of never-treated hypertensive patients.
METHODS
Study population. A total of 262 outpatients at Catanzaro
University Hospital, 130 men and 132 women, age 30 to 55
years (mean  SD  46.1  5.7), with well-documented
history of essential hypertension were included in the study;
225 of them have been included in our previous report (11).
Patient characteristics and inclusion criteria were previously
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described (11). All patients were Caucasian and underwent
physical examination and review of their medical histories.
Causes of secondary hypertension were excluded by clinical
and biochemical tests. At the time of vascular evaluation,
none of the patients had history or clinical evidence of
angina, myocardial infarction, valvular heart disease, diabe-
tes, hyperlipidemia, peripheral vascular disease, coagulopa-
thy, or any disease predisposing them to vasculitis or
Raynaud’s phenomenon. Body mass index (BMI) ranged
from 22 to 28 kg/m2. No participant had ever been treated
with antihypertensive drugs. The local ethics committee
approved the study, and all participants gave written in-
formed consent for all procedures.
BP measurements. Readings of clinic BP were obtained in
the left arm of the supine patients, after 5 min of quiet rest,
with a mercury sphygmomanometer. A minimum of three
BP readings were taken on three separate occasions at least
two weeks apart. Systolic and diastolic BP were recorded at
the first appearance (phase I) and the disappearance (phase
V) of Korotkoff sounds. Baseline BP values were the average
of the last two of the three consecutive measurements
obtained at intervals of 3 min. Patients with a clinic BP
140 mm Hg systolic and/or 90 mm Hg diastolic were
defined as hypertensive.
Ambulatory BP monitorings were obtained by using an
A&D TM-2420/2421 recorder (A&D, Takeda, Japan).
Recordings were taken every 10 min during the day (from
7:00 AM to 11:00 PM) and every 20 min during the night
(from 11:00 PM to 7:00 AM).
Forearm blood flow (FBF) measurements. All studies
were performed at 9:00 AM after overnight fasting, with the
subjects lying supine in a quiet, air-conditioned room (22°C
to 24°C). The subjects were instructed to continue their
regular diet; caffeine, alcohol, and smoking were all allowed
within at least 24 h before the study. Forearm volume was
determined by water displacement. Under local anesthesia
and sterile conditions, a 20-gauge polyethylene catheter
(Vasculon 2, Baxter Healthcare Corp., Deerfield, Illinois)
was inserted into the brachial artery of the nondominant
arm of each subject for evaluation of BP (Baxter Healthcare
Corp.) and for drug infusion. This arm was slightly elevated
above the level of the right atrium, and a mercury-filled
silastic strain-gauge was placed on the widest part of the
forearm. The strain-gauge was connected to a plethysmo-
graph (model EC-4, D.E. Hokanson, Issaquah, Washing-
ton) calibrated to measure the percent change in volume;
this was connected to a chart recorder to obtain the FBF
measurements. A cuff placed on the upper arm was inflated
to 40 mm Hg with a rapid cuff inflator (model E-10, D.E.
Hokanson) to exclude venous outflow from the extremity. A
wrist cuff was inflated to BP values 1 min before each
measurement to exclude the hand blood flow. The antecu-
bital vein of the opposite arm was cannulated.
The FBF was measured as the slope of the change in the
forearm volume. The mean of at least three measurements
was obtained at each time point. Forearm vascular resistance
(VR), as expressed in units, was calculated by dividing mean
BP by FBF.
Vascular function. The protocol, previously described by
Panza et al. (13) and subsequently used by our group
(11,14–16), was employed for the present study. All pa-
tients underwent measurement of FBF and BP during
intra-arterial infusion of saline, ACh, and sodium nitro-
prusside (SNP) at increasing doses. All participants rested
30 min after artery cannulation to reach a stable baseline
before data collection; measurements of FBF and VR,
expressed in units, were repeated every 5 min until stable.
Endothelium-dependent and -independent vasodilation
were assessed by a dose-response curve to intra-arterial ACh
infusions (7.5, 15, and 30 g·ml1·min1, each for 5 min)
and SNP infusions (0.8, 1.6, and 3.2 g·ml1·min1, each
for 5 min), respectively. The sequence of administration of
ACh and SNP was randomized to avoid any bias related to
the order of drug infusion. The drug infusion rate, adjusted
for forearm volume of each subject, was 1 ml/min.
Drugs. Acetylcholine (Sigma, Milan, Italy) was diluted
with saline immediately before infusion. Sodium nitroprus-
side (Malesci, Florence, Italy) was diluted in 5% glucose
solution immediately before each infusion and protected
from light with aluminum foil.
Statistical analysis. Standard descriptive and comparative
analyses were undertaken. The vasodilating responses to
ACh and SNP were compared by analysis of variance
(ANOVA) for repeated measurements and, when analysis
was significant, the Tukey test was applied. The effects of
independent predictors on peak percent increase on FBF
were evaluated by a simple linear regression analysis and,
successively, by a stepwise multiple linear regression with
forward selection. At first, we tested a baseline model by
using the following variables: age, gender, BMI, serum
glucose, serum cholesterol, serum triglycerides, and smoking
habits (previous or current smokers or never smoked).
Subsequent improvements in the model fitting were tested
by entering, one at a time, the different clinic and monitored
BP components: systolic BP, diastolic BP, mean BP, and
PP. Parametric data are reported as mean SD. Significant
differences were assumed to be at p 0.05. All comparisons
were performed using the statistical package SPSS 10.0 for
Windows (SPSS Inc., Chicago, Illinois).
Abbreviations and Acronyms
ACh  acetylcholine
ANOVA  analysis of variance
BMI  body mass index
BP  blood pressure
EDHF  endothelium-derived hyperpolarizing factor
FBF  forearm blood flow
NO  nitric oxide
PP  pulse pressure
SNP  sodium nitroprusside
VR  vascular resistance
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RESULTS
Clinical, humoral, and hemodynamic characteristics of the
study population are reported in Table 1.
Endothelium-dependent vasodilation. Intra-arterial in-
fusion of ACh caused a significant (p  0.0001) dose-
dependent increase in FBF and decrease in forearm VR.
The FBF increments from basal measurements at the three
incremental doses of ACh were as follows: 2.1 1.3 ml100
ml1 of tissue·min1 (65%), 5.1  2.7 ml·100 ml1 of
tissue·min1 (153%), 10.2  4.9 ml·100 ml1 of
tissue·min1 (307%). At the highest dose of ACh (30
g/min), FBF increased to 13.5  5.2 ml·100 ml1 of
tissue·min1 and VR decreased to 10.6  4.9 U. Intra-
arterial infusion of ACh caused no change in BP or heart
rate values.
Endothelium-independent vasodilation. Increasing doses
of intra-arterial infusion of SNP induced a significant (p 
0.0001) increase in FBF as well as a decrease in forearm VR.
The FBF percent increments from basal measurements were
80 38%, 169 63%, and 354 84%; VR decreased from
basal measurements to 22.4  6.4 U, 16.5  4.5 U, and 8.3
 2.3 U, respectively. Intra-arterial infusion of SNP caused
no changes in BP or heart rate values.
Correlational analyses. Initially, we performed a simple
linear regression analysis between the peak percent increase
in both ACh- and SNP-stimulated FBF and the following
variables: age, BMI, serum glucose, serum cholesterol,
serum triglycerides, and both clinic and monitored BP
components (Table 2). As shown in Table 2, age, BMI, and
clinic and monitored systolic BP and PP were significantly
correlated with the peak percent increase in ACh-
stimulated FBF; on the contrary, no significant correlations
were detected using SNP-stimulated FBF as a dependent
variable. In particular, the peak percent increase in FBF
after intra-arterial ACh infusions was inversely related to
clinic systolic BP (r  0.372; p  0.0001) and PP (r 
0.444; p  0.0001), monitored systolic BP (r  0.474;
p 0.0001), and PP (r0.578; p 0.0001), accounting
for 13.9% and 19.8%, and for 22.5% and 33.5% of the
variation in ACh-stimulated FBF, respectively. After linear
regression we performed a stepwise multivariate analysis to
identify the independent predictors of ACh-stimulated
FBF. In this way, we observed that the addition of BP
components to the baseline model (including age, gender
and BMI) that accounts for the 10.5% of the variation,
significantly increased the FBF variation to 22.6% (p 
0.0001) for the clinic systolic BP, 29.9% (p  0.0001) for
the clinic PP, 31.3% (p 0.0001) for the monitored systolic
BP, and 42.8% (p  0.0001) for the monitored PP. The
addition of monitored systolic BP accounts for another 1.1%
of the variation; thus, the total model accounts for 43.9% (p
 0.0001) of FBF variation. As shown in Table 3, the
monitored PP was an independent and strong predictor of
ACh-stimulated FBF, accounting for 33.6% (p  0.0001)
of the variation. When monitored PP and systolic BP were
entered contemporary into the same model, this latter did
not reach statistical significance. Thus, the final model
indicates that for each mm Hg increase in monitored PP,
the ACh-stimulated FBF decreases by 8.7%.
We also evaluated the relationship between the increase
in ACh-stimulated FBF and the distribution of patients
into quartiles according to levels of monitored PP:53 mm
Hg (lower quartile), from 53 to 58 mm Hg (second
quartile), from 58 to 65 mm Hg (third quartile), and 65
mm Hg (upper quartile). The mean peak percent increases
in FBF into quartiles were 430  107, 326  117, 251 
105, and 219  91, respectively (p  0.0001, by ANOVA)
Table 1. Study Population Characteristics
Gender, males/females 130/132
Age, yrs 46.1  5.7
Body mass index, kg/m2 26.2  1.5
Current smokers, % 24.9
Total cholesterol, mmol/l 4.9  0.6
Triglycerides, mmol/l 1.31  0.2
Fasting glucose, mmol/l 5.05  0.5
Clinic systolic BP, mm Hg 158  13
Clinic diastolic BP, mm Hg 94  8
24-h systolic BP, mm Hg 148  10
24-h diastolic BP, mm Hg 89  7
Clinic PP, mm Hg 64  11
24-h PP, mm Hg 59  9
Baseline FBF, ml100 tissue1min1 3.3  0.6
Baseline vascular resistance, U 33.6  5.4
BP  blood pressure; FBF  forearm blood flow; PP  pulse pressure.
Table 2. Results of Univariate Linear Regression Analysis
Between Different Covariates and Peak in ACh- and SNP-
Stimulated Forearm Blood Flow
ACh SNP
r P r P
Age 0.133 0.031 0.087 0.160
Total cholesterol 0.002 0.905 0.080 0.196
Triglycerides 0.095 0.125 0.065 0.297
Body mass index 0.233 0.0001 0.029 0.641
Fasting glucose 0.019 0.763 0.093 0.133
Clinic systolic BP 0.372 0.001 0.093 0.132
Clinic diastolic BP 0.024 0.069 0.037 0.548
Clinic PP 0.444 0.0001 0.090 0.145
24-h systolic BP 0.476 0.0001 0.112 0.270
24-h diastolic BP 0.148 0.523 0.031 0.615
24-h pulse pressure 0.579 0.0001 0.102 0.101
ACh  acetylcholine; BP  blood pressure; PP  pulse pressure; SNP  sodium
nitroprusside.
Table 3. Independent Predictors of Peak Increase in ACh-
Stimulated Forearm Blood Flow After Multivariate Analysis
Partial r2
(%)
Total r2
(%)
Significance
(P)
24-h PP, mm Hg 33.6 33.6 0.0001
Gender, male 4.9 38.5 0.0001
Body mass index, kg/m2 2.5 41.0 0.002
Age, yrs 1.8 42.8 0.005
24-h systolic BP, mm Hg 1.1 43.9 0.05
ACh  acetylcholine; BP  blood pressure; PP  pulse pressure.
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(Fig. 1). The major determinant of the PP increase among
the quartiles was the systolic BP. In fact, systolic BP
increased from 141  6 mm Hg (lower quartile) to 158 
10 mm Hg (upper quartile) (p  0.0001 by ANOVA),
whereas diastolic BP decreased from 93  6 mm Hg (lower
quartile) to 87  9 mm Hg (upper quartile) (p  0.0001 by
ANOVA).
DISCUSSION
In this study, we demonstrated that monitored PP is
inversely related to ACh-stimulated vasodilation in a large
sample of initially untreated and uncomplicated hyperten-
sive patients. This relation persists after adjustment for the
significant influence of other covariates. These data are
consistent with those previously reported in an experimental
animal model demonstrating that PP modulates ACh-
induced, endothelium-dependent responses (12). In addi-
tion, our data outline the accuracy of ambulatory BP to
highlight the association between pressure overload and
hypertension-associated endothelial dysfunction. The
present data also demonstrate that systolic BP rather than
diastolic BP significantly contributes to the increase in PP.
In fact, after partitioning PP in quartiles, the diastolic BP
decreases, from lower to upper quartile, only by 6 mm Hg,
whereas systolic BP increases by 17 mm Hg.
Hypertension and endothelial function. The normal en-
dothelium modulates local blood flow and prevents the
appearance and progression of atherosclerosis through the
dynamic release of different vasoactive factors. Even if many
of the vascular protective actions of endothelium are mainly
dependent on NO production, endothelium-dependent va-
sorelaxation is mediated, at least in part, by other vasoactive
substances, such as EDHF. In particular, the EDHF-
related vasodilation seems to compensate for the impaired
NO-dependent vasodilation in essential hypertension. The
most important endothelium-derived relaxing factor is NO
that may be released after stimulation by endogenous and
pharmacologic agonists and physical stimuli (17–20), such
as flow-mediated shear stress.
On the other hand, it is well known that in forearm
vasculature of hypertensive patients endothelium-dependent
vasodilation is impaired (11,13–16,19–21), accounting for
the increase in VR and for the vascular structural changes.
Nevertheless, other studies indicate that endothelial dys-
function may contribute to the pathogenesis of essential
hypertension by offsetting the balance between vasodilator
and vasoconstrictor forces on vasculature (22,23). This
abnormality, probably multifactorial, is mainly related to a
decreased NO bioavailability that may follow a reduction of
NO synthesis and/or its increased inactivation by oxidative
stress. Thus, endothelial dysfunction, which is characterized
by reduced endothelium-dependent vasodilation and proin-
flammatory, proliferative, and procoagulatory properties
may be considered the initial modification, present in
patients with essential hypertension and other cardiovascu-
lar risk factors, that promotes the coronary and extracoro-
nary atherosclerosis (7,8,17–20). In fact, a dysfunctioning
endothelium increases vascular tone and platelets and
monocytes adhesion, and stimulates the proliferation of
vascular smooth muscle cells and fibroblasts. Moreover,
endothelium modulates other important processes in the
development of atherosclerosis, including inflammation and
thrombosis.
Flow-mediated shear stress and endothelium. The nor-
mal endothelium contributes to the maintenance of a
constant flow-mediated shear stress by releasing vasoactive
agents that modulate vascular diameter. This regulatory
function is clinically relevant because different levels of shear
stress interact with experimental atherogenesis modulating
NO production (24–26). Similarly, human studies have
shown that low flow-mediated shear stress impairs
endothelium-dependent vasodilation both in coronary (27)
and peripheral (28) conductance arteries.
Interestingly, flow pulsatility, but not turbulent flow, was
observed at the sites of atherosclerotic plaques (29). Thus,
on the basis of these observations, it is evident that oscilla-
tory and steady laminar shear stress exert differential effects
on endothelial cells. Indeed, De Keulenaer et al. (30) have
recently reported that continuous oscillatory shear stress
causes a sustained activation of prooxidant processes result-
ing in redox-sensitive gene expression in human umbilical
endothelial cells. The findings by De Keulenaer were
extended by Silacci et al. (31), who showed that pulsatile
flow increases endothelial oxidative stress similar to oscilla-
tory flow conditions. These findings may be explained by
the up-regulation of NO synthase III with a mechanism
involving, at least in part, the activation of the nuclear
factor-kappa B resulting in an increase of oxidative stress. In
keeping with these, laminar flow-mediated shear stress
rather than oscillatory shear stress appears to exert protective
antiatherosclerotic vascular effects.
Figure 1. Blood pressure (bars) and peak percent increase in forearm blood
flow (line) values by quartiles of pulse pressure are graphically reported. It
is evident that forearm blood flow values progressively decrease from lower
to upper quartile of pulse pressure. The picture also demonstrates the
contribution of both systolic and diastolic blood pressure (dark zone) to
increase in pulse pressure. Particularly, from lower to upper quartile of
pulse pressure, systolic blood pressure increases by 17 mm Hg, whereas
diastolic blood pressure decreases by 6 mm Hg.
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BP and flow-mediated shear stress. It is well established
that local factors and vascular geometry modulate the blood
flow pattern and velocity and, thus, the level of flow-
mediated shear stress (32). An increase in vascular diameter
may account for the observed inverse relationship between
systolic BP and wall shear stress (33). Thus, vascular
changes induced by hypertension may affect the magnitude
of flow-mediated shear stress and, thereby, NO production.
In arterial BP it is possible to recognize a steady compo-
nent, as mean BP, and a pulsatile component, as PP. Major
determinants of mean BP are considered ventricular ejection
and peripheral VR, whereas ventricular ejection and vascular
wall stiffness contribute to PP (34). Therefore, it is reason-
able to hypothesize that the same experimental mechanisms
are operating in the endothelial dysfunction of human
hypertension. Consistent with this hypothesis, even if we
did not measure the oxidative stress, it is possible to
speculate that elevation in PP reduces ACh-stimulated
vasodilation by increasing oxidative stress and reducing NO
production as consequence of low shear stress. These
mechanisms, even if they remain still too speculative, are
consistent with previous experimental findings (28–31). On
the other hand, Wilkinson and coworkers (35) recently
demonstrated that endogenous NO regulates arterial dis-
tensibility in vivo, whereby an increase in endothelium-
derived NO is associated with reduced arterial stiffness.
Thus, it is equally plausible that reduced NO bioavailability
induces a PP elevation and that increase in PP reduces NO
production, supporting the concept that an elevated PP is
both a cause and a consequence of atherosclerosis (4).
Clinical implications. Increase in PP has been related to
cardiac and vascular hypertrophy (36), coronary heart disease
(1,3), and subsequent cardiovascular events, resulting in a good
or better predictor than other BP components (1–4). There-
fore, consistent with these findings, it might be useful to
consider PP an important and new clinical predictor to define
the total cardiovascular risk profile of hypertensive patients.
Even if it is premature to identify the reduction of PP as
a therapeutic goal, it is reasonable to affirm that cardiovas-
cular risk in hypertensive patients could be further reduced
by narrowing the pulsatile component of BP at any reduc-
tion in mean BP. Angiotensin-converting enzyme inhibi-
tors, calcium channel blockers, and low-dose diuretics seem
to be effective in improving arterial distensibility (4).
Conclusions. The present study demonstrates that PP is a
strong independent predictor of endothelium-dependent
ACh-stimulated vasodilation in hypertensive patients. This
response probably is mediated by magnitude and type of shear
stress. Finally, our findings extend previous observations about
possible mechanisms operating in endothelial function.
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